about
Emerging drugs of abuse: current perspectives on synthetic cannabinoidsReports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2013-2016: A Review.Annual banned-substance review: analytical approaches in human sports drug testing.Identification and characterization of new designer drug 4-fluoro-PV9 and α-PHP in the seized materialsReinforcing Effects of Cathinone NPS in the Intravenous Drug Self-Administration Paradigm.When "Chems" Meet Sex: A Rising Phenomenon Called "ChemSex".A Curious Case of Inhalation Fever Caused by Synthetic Cannabinoid.Novel Psychoactive Substances-Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs.Inhaled Loxapine for Agitation in Intoxicated Patients: A Case Series.Drugs of Abuse and Novel Psychoactive Substances at Outdoor Music Festivals in Colorado.Fatal Mesenteric Ischemia Induced by Synthetic Cannabinoids: A Case Report and Literature Review.The newest cathinone derivatives as designer drugs: an analytical and toxicological review.Gas Chromatography Mass Spectrometry (GC-MS) for Identification of Designer Stimulants Including 2C Amines, NBOMe Compounds, and Cathinones in Urine.Locomotor and discriminative stimulus effects of four novel hallucinogens in rodents.Intracerebral Hemorrhage with Multiple Intracranial Arterial Stenoses in a Synthetic Cannabinoid "Spice" User.Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective.The Chameleon-Like Properties of Psychoactive Drugs: Examinations with HR LC-MS/MS Technology of Patients Presenting at the Emergency Department Following the Use of Synthetic Cannabinoids: A Case Series and Literature Review
P2860
Q26778885-ACC114A0-5A6A-4127-8020-6C48D0E7CD57Q30148688-EEE688E5-89FB-4949-A762-9A4B9D856CDDQ34509038-89131091-43CA-45AB-8502-C4F82FFBE410Q34510174-54E2750A-4A0A-465C-BB48-F34394C2B85DQ38840376-E8FF53E6-9110-4CEE-A4BC-A7B7AC450901Q39010900-C9457A96-428A-4E9F-ACC9-2A2D780129F3Q40102790-89C963E3-AB5F-42B4-8942-023D435E0013Q41462770-9D1B2B95-5096-41E6-B2CD-F309D898AFC4Q42697689-39D01156-B155-4258-948B-A0C850478305Q47306703-0DD4B894-C05E-40D5-AB75-AD4819419A54Q48102319-A8A353EE-8537-45FC-896B-A1FE0A2850F5Q49723300-DD9444C0-F75B-4BE7-A517-8785B52C4597Q50105392-2AB5E609-1D68-4745-810D-4AE2D11B4111Q50627353-4122FAEE-2907-49C5-9661-B7593E3D862FQ54940339-291528B5-91A8-4BAA-80EB-0A86508437D1Q55384363-BD70D103-689D-46AB-89AE-E918BB354F11Q58702071-6FBDD8DD-C70F-4A9A-B102-AFA13E498806
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Designer drugs 2015: assessment and management.
@ast
Designer drugs 2015: assessment and management.
@en
type
label
Designer drugs 2015: assessment and management.
@ast
Designer drugs 2015: assessment and management.
@en
prefLabel
Designer drugs 2015: assessment and management.
@ast
Designer drugs 2015: assessment and management.
@en
P2093
P2860
P1476
Designer drugs 2015: assessment and management.
@en
P2093
Erik W Gunderson
John A Hopper
Michael F Weaver
P2860
P2888
P356
10.1186/S13722-015-0024-7
P577
2015-03-25T00:00:00Z
P5875
P6179
1001112826